Breaking Finance News

Verastem Inc (NASDAQ:VSTM) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Zacks Investment Research has upgraded Verastem Inc (NASDAQ:VSTM) to Hold in a statement released on 5/25/2017.

Having a price of $2.40, Verastem Inc (NASDAQ:VSTM) traded -2.81% lower on the day. With the last close down 45.41% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.02% over the same period. VSTM has recorded a 50-day average of $4.59 and a two hundred day average of $3.09. Trade Volume was down over the average, with 430,753 shares of VSTM changing hands under the typical 1,329,690

Recent Performance Chart

Verastem Inc (NASDAQ:VSTM)

Verastem Inc has with a one year low of $1.05 and a one year high of $5.71 and has a market capitalization of $0.

General Company Details For Verastem Inc (NASDAQ:VSTM)

Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company's VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company's VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *